Pharmacogenetic analysis of human steroid 5α reductase type II: comparison of finasteride and dutasteride
June 2005
in “Journal of Molecular Endocrinology”
TLDR Dutasteride is more efficient than finasteride, but individual results vary.
This study analyzed the pharmacogenetics of finasteride and dutasteride, two drugs used to treat prostatic diseases. The study found that both drugs are slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being a more efficient inhibitor than finasteride for most enzyme variants. However, there is significant pharmacogenetic variation for both drugs, which should be taken into account when designing treatment protocols. The study suggests that pharmacogenetic analysis could be used to determine which drug would be most effective for individual patients.
View this study on jme.bioscientifica.com →
Cited in this study
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research 5α-reductase inhibitors/finasteride
Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
research Finasteride: A slow-binding 5.alpha.-reductase inhibitor
Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.
Related
research FINASTERIDE INHIBITS 5?-REDUCTASE ACTIVITY IN HUMAN DERMAL FIBROBLASTS: PREDICTION OF ITS THERAPEUTIC APPLICATION IN ANDROGEN-RELATED SKIN DISEASES
Finasteride helps treat skin issues like acne and baldness by blocking testosterone conversion.
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.
Finasteride doesn't affect hormone levels in normal men.
research The clinical development of a 5α-reductase inhibitor, finasteride
Finasteride effectively treats BPH, but needs more trials to understand potential.